LuPIN abstract, page-7

LuPIN data published today makes it likely, in my opinion, that Novartis will WANT to do a deal with Noxopharm.

Median survival for all 56 end-stage prostate patients was 19.7 months, a significant improvement over the 17.1 months reported for the low-dose patients. It is actually better than it sounds.

LuPIN patients were more resistant to treatment than those enrolled in the VISION registration trial being conducted by Endocyte/Novartis, having had to have failed more prior therapies. VISION is expected to achieve median survival of about 13.5 months, based on results from a trial that enrolled 50 similar patients. It is remarkable that the addition of Veyonda was able to extend median survival by 6 months, to 19.7 months, in harder-to-treat patients.